Skip to Content

J&J Told to Pay $257.7 Million Over Risperdal Marketing

BRIEF: J&J Told To Pay $257.7M Over Risperdal Marketing Tactics [The Indianapolis Star]

From Indianapolis Star (IN) (October 15, 2010)

Oct. 15--Johnson & Johnson lost a $257.7 million jury verdict in Louisiana for making misleading claims about the safety of the company’s Risperdal antipsychotic drug, Bloomberg reported.

J&J officials defrauded the state’s Medicaid system by wrongfully touting Risperdal as superior to competing antipsychotic drugs and minimizing its links to diabetes, said jurors in state court in Opelousas, La.

Thursday’s verdict is the second trial loss in a state lawsuit brought over Risperdal marketing. A West Virginia judge in a non-jury trial last year awarded $3.95 million, finding the company misled doctors about the risks and benefits of Risperdal. New Brunswick, N.J.-based J&J appealed.

To see more of The Indianapolis Star or to subscribe to the newspaper, go to

Copyright (c) 2010, The Indianapolis Star

Distributed by McClatchy-Tribune Information Services.

For more information about the content services offered by McClatchy-Tribune Information Services (MCT), visit, e-mail, or call 866-280-5210 (outside the United States, call +1 312-222-4544)


Posted: October 2010